Drug intelligence / Profile preview

CMAB023

Development stage: Preclinical
Lead developer: Mabpharm
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

CMAB023 is a biosimilar monoclonal antibody developed by Mabpharm that targets thymic stromal lymphopoietin (TSLP). TSLP is an epithelial-derived cytokine that plays a critical role in the upstream initiation of the inflammatory cascade in asthma, influencing both Type 2 (Th2) and non-Type 2 inflammatory pathways. By binding to and neutralizing TSLP, CMAB023 is designed to prevent the cytokine from interacting with its receptor complex, thereby reducing airway inflammation and preventing asthma exacerbations. The drug is currently in the IND-enabling stage of development for the treatment of severe asthma in adults and pediatric patients aged 12 years and older.

Targets

TSLP (Thymic stromal lymphopoietin)

Beyond the preview

Go deeper on CMAB023.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CMAB023.

Explore the full profile